MASH Innovator Drug Partnerships Surge Over $2.5 Billion In 2024YTD, Reveals GlobalData
Biopharmaceutical companies are regaining interest in metabolic dysfunction-associated steatohepatitis (MASH) innovator drug development. MASH innovator drugs witnessed over $2.5 billion increase in the total value of partnership deals from 2020 to 2024 …